INTERLINK COE Networks & Programs’ Post

FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors On June 13, 2024, the Food and Drug Administration granted accelerated approval to repotrectinib (AUGTYRO, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy. #fda #drugapproval #oncology https://lnkd.in/g2tx7wg6

In a conversation with Luisa Torres, PhD of Drug Discovery News, Kyverna Therapeutics Chief Medical Officer James Chung discusses the potential of CAR T-cell therapy for multiple sclerosis, gives an update on #KYV101’s clinical progress, and expresses his enthusiasm for the future of autoimmune disease research at Kyverna. Chung also shares how there is an opportunity to use CAR T cells to test the hypothesis about B cell depletion in a more complete way and to see if there could be unprecedented levels of efficacy. #CARTcelltherapy #AutoimmuneDisease #MultipleSclerosis https://lnkd.in/eqTBG8Yw

#celltherapy to treat #autoimmune disease is the next treatment frontier as adoptive cellular therapies move beyond oncology and into other larger, more prevalent diseases with high unmet clinical need. Learn more about this emerging treatment modality in the story below... #advancedtherapies #cartcelltherapy

If you are interested in #cellcycle science and its impact on innovative #breastcancer therapeutics, check out our recent work seamlessly integrating biological and #drugdevelopment perspectives in Clinical and Translational Medicine

More than 2 years ago, Healio reported on the groundbreaking cohort of #lupus patients undergoing #CART cell therapy and the explosive potential to treat the most severe and refractory forms of #AutoimmuneDisease 💥 2 years later, are we still waiting for the boom? 💥 “All five SLE patients are in remission and drug-free,” Dr. Georg Schett, whose lab produced the landmark 2022 study, said. “All of them are now 2 years disease-free, and the first of them is now 3 years disease free.” Since then, the potential for #CART cell therapy has proliferated across the rheumatology spectrum: 🔬 New data accrued for autoimmune myositis, #SystemicSclerosis and #MyastheniaGravis 💉 First treatments given in neuromyelitis optica and #MultipleSclerosis 👩⚕️ Potential indications for #RheumatoidArthritis, #Sjogrens syndrome, ANCA-associated #vasculitis and blistering skin diseases It is too soon to call CAR T cell therapy a “cure,” but this kind of excitement is rare in the #rheumatology space, and we are cautiously optimistic that – despite the checkered history of rheumatology therapies – this will lead to effective treatments in the most hard-to-treat populations 🤞 Join the conversation 💬

Brainstorm Cell Therapeutics Announces Peer-reviewed Publication of #Biomarker Data from NurOwn's® Phase 3 Clinical Trial in #ALS. NurOwn treatment resulted in a positive impact on important #CSF biomarkers relevant to ALS compared to placebo. Significant changes in multiple ALS disease pathways support NurOwn's mechanism of action and complement clinical effects observed in ALS. https://lnkd.in/gv7R7FY3

Antibody drug conjugates (ADCs) are fast-growing fields and attract strong interests from antibody professionals. We are highlighting selected ADCs papers published on Antibody Therapeutics (current CiteScoreTracker: 8.3), official journal of the Chinese Antibody Society. The 5th paper was entitled “Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities” contributed by Wenjin Wu from U.S. Food and Drug Administration (FDA). We also highly recommend the special Issue Collection: Antibody-targeted Cytotoxic agents – Immunotoxins and ADCs. This special issue collection includes 14 excellent review and research articles. Special thanks to the two guests, Dr. Antonella Antignani and Dr. David FitzGerald at National Cancer Institute (NCI) of The National Institutes of Health. You may find more ADCs collection through https://lnkd.in/e76efmRZ #ADCs #Antibody #Therapeutics #Immunotoxins

I love examples of how relatively simple (not requiring complicated genetic engineering) process changes can lead to significant improvements in CAR T cell function. These authors show how glucose-based to galactose-based media leads to increased mitochondrial activity and improved tumor control: https://lnkd.in/gmQdWAnf. Maybe this approach could be combined with low oxygen culture...? #cellandgenetherapy #biotechnology #lifesciences #manufacturing #manufacturingreadiness #advancedtherapies #therapeutics #pharma #pharmaceuticals #manufacturingtools #carttherapies #oncology #efficacy #potency

📉 Impact ⤵ TG Therapeutics, Inc. has secured FDA clearance to begin a Phase I trial of #AzercabtageneZapreleucel (azer-cel), a novel allogeneic #CARTtherapy for progressive multiple sclerosis. This milestone marks a significant step forward in exploring CAR T technology beyond oncology, potentially offering new hope for patients with #chronicautoimmunediseases. 💡 Insight ⤵ The expansion of allogeneic CAR T therapy into autoimmune diseases like multiple sclerosis reflects the growing potential of innovative treatments in addressing unmet medical needs. This partnership between Precision BioSciences and TG Therapeutics highlights the importance of collaboration in advancing groundbreaking therapies that could transform patient care. ❓ Questions to Think About ⤵ How will the success of azer-cel influence the future of CAR T therapies in autoimmune diseases? What challenges might arise in translating oncology-focused CAR T technology to autoimmune conditions? How could this trial reshape treatment approaches for multiple sclerosis? #PharmaNews #CARTTherapy #MultipleSclerosis #AutoimmuneDisease #PrecisionMedicine #TGtherapeutics #HealthcareInnovation #GeneEditing #Biotech

Great article on CAR-T therapies for Lupus. Thought I'd add to the report with some additional numbers pulled from Beacon Immune Tolerance. - 61 cell therapy assets investigating SLE - 22 of these have already published preclinical efficacy readouts - 33/61 being specifically CAR-T - 360 assets investigating SLE across all drug modalities - with 72 of these drugs in preclinical dev. vs. 244 in the clinic Happy to dive deeper into these numbers for anyone who's interested. #sle #autoimmune #cartcelltherapy https://lnkd.in/exSj8z7i